In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Henkel first quarter

This article was originally published in The Rose Sheet

Executive Summary

Cosmetics/toiletries division sales fell 3.8% to $573.7 mil. (€1=$1.17) in Q1, Henkel announces June 5. After adjusting for currency effects, division sales were flat over prior-year period. Sales in Europe/ Africa/Middle East region were even with a year ago, while sales in North America declined. Division earnings before interest and taxes were virtually unchanged at $49.2 mil. Henkel consolidated sales fell 3.1% on a reported basis to $2.74 bil., and earnings before interest and taxes increased 3.5% to $196.7 mil. In comments to analysts regarding Henkel's minority stake in Wella, CEO Ulrich Lehner says the difference in price offered by Procter & Gamble for voting shares and preference shares remains a "big stretch." The exec provided no additional comment on how Henkel will proceed with the tender offer...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011265

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel